New dosing strategy aims to reduce eye side effects in myeloma drug
NCT ID NCT05064358
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This study tested different doses and schedules of the drug belantamab mafodotin in 177 adults with multiple myeloma that had returned or not responded to at least three prior treatments. The goal was to see if changing the dose could reduce serious eye problems while still controlling the cancer. Participants received one of several dosing regimens, and researchers tracked eye health and cancer response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
West Palm Beach, Florida, 33401, United States
-
GSK Investigational Site
Kansas City, Missouri, 64114, United States
-
GSK Investigational Site
New York, New York, 10065, United States
-
GSK Investigational Site
Chattanooga, Tennessee, 37404, United States
-
GSK Investigational Site
Nashville, Tennessee, 37203, United States
-
GSK Investigational Site
Houston, Texas, 77090, United States
-
GSK Investigational Site
Buenos Aires, C1181ACH, Argentina
-
GSK Investigational Site
Capital Federal, C1426ANZ, Argentina
-
GSK Investigational Site
Ciudad Autonoma de Buenos Aire, 1414, Argentina
-
GSK Investigational Site
Pilar, B1629AHJ, Argentina
-
GSK Investigational Site
Rosario, S2002, Argentina
-
GSK Investigational Site
Liverpool, New South Wales, 2170, Australia
-
GSK Investigational Site
Newcastle, New South Wales, 2298, Australia
-
GSK Investigational Site
Woodville, South Australia, 5011, Australia
-
GSK Investigational Site
East Melbourne, Victoria, 3002, Australia
-
GSK Investigational Site
Joinville, 89201-260, Brazil
-
GSK Investigational Site
Porto Alegre, 90850-170, Brazil
-
GSK Investigational Site
Rio de Janeiro, 22271-110, Brazil
-
GSK Investigational Site
Salvador, 41253-190, Brazil
-
GSK Investigational Site
São Paulo, 01236-030, Brazil
-
GSK Investigational Site
São Paulo, 04537-080, Brazil
-
GSK Investigational Site
Montreal, Quebec, H4J 1C5, Canada
-
GSK Investigational Site
Avignon, 84902, France
-
GSK Investigational Site
Nice, 06189, France
-
GSK Investigational Site
Orléans, 45100, France
-
GSK Investigational Site
Cottbus, 03048, Germany
-
GSK Investigational Site
Dresden, 01307, Germany
-
GSK Investigational Site
Greifswald, 17475, Germany
-
GSK Investigational Site
Hamburg, 22763, Germany
-
GSK Investigational Site
Athens, 106 76, Greece
-
GSK Investigational Site
Athens, 11528, Greece
-
GSK Investigational Site
Athens, 12462, Greece
-
GSK Investigational Site
Rio Patras, 26504, Greece
-
GSK Investigational Site
Dublin, 8, Ireland
-
GSK Investigational Site
Dublin, D09 V2N0, Ireland
-
GSK Investigational Site
Alessandria, 15121, Italy
-
GSK Investigational Site
Ascoli Piceno, 63100, Italy
-
GSK Investigational Site
Ferrara, 44124, Italy
-
GSK Investigational Site
Genova, 16132, Italy
-
GSK Investigational Site
Meldola FC, 47014, Italy
-
GSK Investigational Site
Reggio Emilia, 42123, Italy
-
GSK Investigational Site
Rimini, 47900, Italy
-
GSK Investigational Site
Mexico City, 03100, Mexico
-
GSK Investigational Site
Mexico City, 03720, Mexico
-
GSK Investigational Site
Bydgoszcz, 85-168, Poland
-
GSK Investigational Site
Gdansk, 80-214, Poland
-
GSK Investigational Site
Katowice, 40-519, Poland
-
GSK Investigational Site
Lublin, 20-081, Poland
-
GSK Investigational Site
Poznan, 60-569, Poland
-
GSK Investigational Site
Torun, 87-100, Poland
-
GSK Investigational Site
Warsaw, 02-781, Poland
-
GSK Investigational Site
Wałbrzych, 58-309, Poland
-
GSK Investigational Site
Wroclaw, 50-367, Poland
-
GSK Investigational Site
Hwasun, 58128, South Korea
-
GSK Investigational Site
Pusan, 49241, South Korea
-
GSK Investigational Site
Seoul, 03080, South Korea
-
GSK Investigational Site
Seoul, 06591, South Korea
-
GSK Investigational Site
Albacete, 02006, Spain
-
GSK Investigational Site
Barcelona, 08026, Spain
-
GSK Investigational Site
Córdoba, 140044, Spain
-
GSK Investigational Site
Girona, 17007, Spain
-
GSK Investigational Site
Oviedo, 33011, Spain
-
GSK Investigational Site
Terrassa - Barcelona, 08221, Spain
-
GSK Investigational Site
Valencia, 46010, Spain
-
GSK Investigational Site
Bern, 3010, Switzerland
-
GSK Investigational Site
Taichung, 404, Taiwan
-
GSK Investigational Site
Taichung, 40705, Taiwan
-
GSK Investigational Site
Tainan, 704, Taiwan
-
GSK Investigational Site
Taipei, 100, Taiwan
-
GSK Investigational Site
Taipei, 112, Taiwan
-
GSK Investigational Site
Bangkok, 10210, Thailand
-
GSK Investigational Site
Bangkok, 10330, Thailand
-
GSK Investigational Site
Chiang Mai, 50200, Thailand
-
GSK Investigational Site
Khon Kaen, 40002, Thailand
-
GSK Investigational Site
Leicester, LE1 5WW, United Kingdom
-
GSK Investigational Site
London, W12 0HS, United Kingdom
-
GSK Investigational Site
Stoke-on-Trent, ST4 6QG, United Kingdom
Conditions
Explore the condition pages connected to this study.